A health worker holds a vial of Covid-19 vaccine (left) and “Gam-COVID-Vac” (also known as ” Sputnik V”) (right) vials.
The outbreak of the Chinese communist virus in India is rapidly worsening under the influence of a variant strain of the virus that is suspected of spreading faster. In addition to strengthening preventive measures, the Indian medical regulator yesterday (12) also approved the third vaccine, Russian Satellite-V (Sputnik-V), for emergency use.
India in the past 24 hours more than 160,000 new cases, the cumulative cases so far exceeded 13.69 million cases, the number of deaths also reached 171,098 people. In the rapid deterioration of the epidemic around the Prime Minister Modi last week still ruled out the possibility of another national blockade, but the most serious epidemic in Maharashtra province (Maharashtra) and many other places are rumored that the local government may again implement a total blockade or city closure news.
The Drug Controller General of India (DCGI) announced on December 12 that it had granted emergency access to the Sat-V vaccine after an expert committee gave the green light to the Russian vaccine.
The Russian Direct Investment Fund (RDIF), which owns the Sat-V vaccine, issued a statement saying that RDIF has reached an agreement with five other Indian pharmaceutical companies, including Gland Pharma, to produce 850 million doses of the vaccine annually.
RDIF believes that the first dose of Sat-V vaccine will be delivered in late April or May, and is certain that a small amount of Sat-V vaccine will be available in May, but it will take a few months to increase productivity, and believes that by June, India will have real capacity, said Kirill Dmitriev, executive director of the Russian Direct Investment Fund.
The satellite-V vaccine is also the third vaccine to be granted emergency access by Indian drug regulatory authorities, the first two being developed by British drug companies AstraZeneca and Oxford University and manufactured by the Serum Institute of India Covishield vaccine (same ingredients as AZ vaccine), and COVAXIN vaccine developed locally and manufactured by Bharat Biotech International in India.
The Satellite-V vaccine has a claimed efficacy rate of 91.6%, second only to Moderna (95.8%) in the UK and the vaccine developed by Pfizer and BioNTech (95.8%) in Germany. India expects that the addition of this vaccine will alleviate the current surge in demand for vaccination due to the worsening epidemic.
Recent Comments